Evidence map›Paper›PMID 34253291›Full record

ArticleeLife2021

Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world.

Jaspreet Toor, Susy Echeverria-Londono, Xiang Li, Kaja Abbas, Emily D Carter, Hannah E Clapham, Andrew Clark, Margaret J de Villiers, Kirsten Eilertson, Matthew Ferrari and 37 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Strength and weakness of disease-induced herd immunity in networks.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  11. Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors at 17 institutions in 7 countries.

Jaspreet Toor *MRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0003-1510-397X
Susy Echeverria-Londono *MRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.
Xiang Li *MRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.
Kaja AbbasLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Emily D CarterBloomberg School of Public Health, Johns Hopkins University, Baltimore, United States.
Hannah E ClaphamSaw Swee Hock School of Public Health, National University of Singapore, Singapore; Oxford University Clinical Research Unit, Vietnam; Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.ORCID 0000-0002-2531-161X
Andrew ClarkLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Margaret J de VilliersMRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.
Kirsten EilertsonColorado State University, Fort Collins, United States.
Matthew FerrariPennsylvania State University, State College, United States.
Ivane GamkrelidzeCenter for Disease Analysis Foundation, Lafayette, United States.
Timothy B HallettMRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.
Wes R HinsleyMRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.
Daniel HoganGavi, the Vaccine Alliance, Geneva, Switzerland.
John H HuberDepartment of Biological Sciences, University of Notre Dame, Notre Dame, United States.
Michael L JacksonKaiser Permanente Washington, Seattle, United States.
Kevin JeanMRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0001-6462-7185
Mark JitLondon School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0001-6658-8255
Andromachi KarachaliouUniversity of Cambridge, Cambridge, United Kingdom.
Petra KlepacLondon School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0003-4132-3933
Alicia KraayRollins School of Public Health, Emory University, Atlanta, United States.
Justin LesslerBloomberg School of Public Health, Johns Hopkins University, Baltimore, United States.ORCID 0000-0002-9741-8109
Xi LiIndependent, Atlanta, United States.
Benjamin A LopmanRollins School of Public Health, Emory University, Atlanta, United States.
Tewodaj MengistuGavi, the Vaccine Alliance, Geneva, Switzerland.ORCID 0000-0003-3475-3599
C Jessica E MetcalfPrinceton University, Princeton NJ, United States.ORCID 0000-0003-3166-7521
Sean M MooreDepartment of Biological Sciences, University of Notre Dame, Notre Dame, United States.ORCID 0000-0001-9062-6100
Shevanthi NayagamMRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.
Timos PapadopoulosPublic Health England, London, United Kingdom.
T Alex PerkinsDepartment of Biological Sciences, University of Notre Dame, Notre Dame, United States.ORCID 0000-0002-7518-4014
Allison PortnoyCenter for Health Decision Science, Harvard T H Chan School of Public Health, Harvard University, Cambridge, United States.
Homie RazaviCenter for Disease Analysis Foundation, Lafayette, United States.
Devin Razavi-ShearerCenter for Disease Analysis Foundation, Lafayette, United States.
Stephen ReschCenter for Health Decision Science, Harvard T H Chan School of Public Health, Harvard University, Cambridge, United States.
Colin SandersonLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Steven SweetCenter for Health Decision Science, Harvard T H Chan School of Public Health, Harvard University, Cambridge, United States.
Yvonne TamBloomberg School of Public Health, Johns Hopkins University, Baltimore, United States.
Hira TanvirLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Quan Tran MinhDepartment of Biological Sciences, University of Notre Dame, Notre Dame, United States.
Caroline L TrotterUniversity of Cambridge, Cambridge, United Kingdom.
Shaun A TrueloveBloomberg School of Public Health, Johns Hopkins University, Baltimore, United States.ORCID 0000-0003-0538-0607
Emilia VynnyckyPublic Health England, London, United Kingdom.
Neff WalkerBloomberg School of Public Health, Johns Hopkins University, Baltimore, United States.
Amy WinterBloomberg School of Public Health, Johns Hopkins University, Baltimore, United States.
Kim WoodruffMRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0003-4618-8267
Neil M FergusonMRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.
Katy Am GaythorpeMRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0003-3734-9081
Imperial College London · GBJohns Hopkins University · USLondon School of Hygiene & Tropical Medicine · GBUniversity of Notre Dame · USCenter for Disease Analysis · USHarvard University · USEmory University · USGavi · CHPublic Health England · GBUniversity of Cambridge · GBColorado State University · USConservatoire National des Arts et Métiers · FRKaiser Permanente · USNational University of Singapore · SGPennsylvania State University · USPrinceton University · USUniversity of London · GB

Funding

Modeling the impact and cost-effectiveness of next-generation rotavirus vaccine strategies in low- and middle-income countriesR01AI112970 · NIAID · YALE UNIVERSITY · PI PITZER, VIRGINIA E · 2015 to 2024
$4.1M
Preparing for the SARS-CoV2 vaccine: Modeling of transmission pathways, viral evolution and vaccination strategiesR01GM124280 · NIGMS · EMORY UNIVERSITY · PI LOPMAN, BENJAMIN A · 2018 to 2022
$2.2M
Medical Research Council MR/R015600/1NIAID NIH HHS R01 AI112970NIGMS NIH HHS R01 GM124280NIH HHS R01 AI112970NIH HHS R01 GM124280
6 · The paper itself

Abstract

Background: Vaccination is one of the most effective public health interventions. We investigate the impact of vaccination activities for Methods: Twenty-one mathematical models estimated disease burden using standardised demographic and immunisation data. Impact was attributed to the year of vaccination through vaccine-activity-stratified impact ratios. Results: We estimate 97 (95%CrI[80, 120]) million deaths would be averted due to vaccination activities over 2000-2030, with 50 (95%CrI[41, 62]) million deaths averted by activities between 2000 and 2019. For children under-5 born between 2000 and 2030, we estimate 52 (95%CrI[41, 69]) million more deaths would occur over their lifetimes without vaccination against these diseases. Conclusions: This study represents the largest assessment of vaccine impact before COVID-19-related disruptions and provides motivation for sustaining and improving global vaccination coverage in the future. Funding: VIMC is jointly funded by Gavi, the Vaccine Alliance, and the Bill and Melinda Gates Foundation (BMGF) (BMGF grant number: OPP1157270 / INV-009125). Funding from Gavi is channelled via VIMC to the Consortium's modelling groups (VIMC-funded institutions represented in this paper: Imperial College London, London School of Hygiene and Tropical Medicine, Oxford University Clinical Research Unit, Public Health England, Johns Hopkins University, The Pennsylvania State University, Center for Disease Analysis Foundation, Kaiser Permanente Washington, University of Cambridge, University of Notre Dame, Harvard University, Conservatoire National des Arts et Métiers, Emory University, National University of Singapore). Funding from BMGF was used for salaries of the Consortium secretariat (authors represented here: TBH, MJ, XL, SE-L, JT, KW, NMF, KAMG); and channelled via VIMC for travel and subsistence costs of all Consortium members (all authors). We also acknowledge funding from the UK Medical Research Council and Department for International Development, which supported aspects of VIMC's work (MRC grant number: MR/R015600/1).JHH acknowledges funding from National Science Foundation Graduate Research Fellowship; Richard and Peggy Notebaert Premier Fellowship from the University of Notre Dame. BAL acknowledges funding from NIH/NIGMS (grant number R01 GM124280) and NIH/NIAID (grant number R01 AI112970). The Lives Saved Tool (LiST) receives funding support from the Bill and Melinda Gates Foundation.This paper was compiled by all coauthors, including two coauthors from Gavi. Other funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Indexed as

COVID-19Global HealthModels, BiologicalSARS-CoV-2Bacterial InfectionsBacterial VaccinesHumansBacterial Vaccinesepidemiologyglobal healthLMICsmathematical modellingvaccine impactvirus

Identifiers

PMID34253291
PMCPMC8277373
OpenAlexW3181487322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.